Supportively, Feng et al. found that overexpression of LAT2 in a pancreatic xenograft mouse model led to reduced sensitivity to gemcitabine, as indicated by a non-significant difference in tumor volume between the gemcitabine-treated group and the control group18. This evidence concerns the gene LAT2 and neoplasm.